Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by jawcellison Jun 17, 2015 8:32am
154 Views
Post# 23838683

SIAL and Sigma Aldrich

SIAL and Sigma AldrichHow or does this effect TLT? thanks

News Story

print Printreset Resethelp Help
Deal snapshot: EU, CHINA REGULATORS CLEAR GERMAN MERCK TO BUY SIGMA ALDRICH

06/16/2015 06:50 PM ET

Jun 16, 2015 (M&A Navigator via COMTEX News Network) -- The European Commission has conditionally cleared the planned acquisition of US-based life sciences company Sigma-Aldrich Corp. (NASDAQ: SIAL) by German drugmaker Merck KGaA, the companies said. Sigma-Aldrich also announced it has obtained full clearance of the transaction from the Chinese Ministry of Commerce. These latest jurisdictions to clear the transaction follow clearance in May by Japanese authorities. Antitrust clearance has also been obtained in the United States, Russia, Serbia, Ukraine, South Africa and Taiwan. On September 22, 2014, Merck KGaA, Darmstadt, Germany, and Sigma-Aldrich announced they had entered into a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for USD 17bn, or USD 140 cash per share.
Country: USA
Sector: Pharmaceuticals
Target: Sigma-Aldrich Corp
Buyer: Merck KGaA
Vendor:
Deal size in USD: 17bn
Type: Corporate Acquisition
Financing:
Status: Agreed
Buyer advisor: , ,
Comment:

 Comments on this story may be sent to info@m2.com  

(C)2015 M2 COMMUNICATIONS https://www.m2.com


Bullboard Posts